Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Roche (SWX:ROG) said Avastin bevacizumab plus Tarceva erlotinib and gemcitabine missed the primary
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury